Products for Research Use Only

ENMD-2076

CAT: 0804-HY-10987A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10987A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
CAS Number
934353-76-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Aurora Kinase; FGFR; FLT3; PDGFR; Src; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/enmd-2076.html
Purity
99.99
Solubility
DMSO : ≥ 31 mg/mL
Smiles
CC1=CC(NC2=NC(/C=C/C3=CC=CC=C3)=NC(N4CCN(CC4)C)=C2)=NN1
Molecular Formula
C21H25N7
Molecular Weight
375.47
Precautions
H302, H315, H319, H335
References & Citations
[1]Fletcher GC, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011 Jan;10 (1) :126-37.|[2]Wang X, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010 Aug;150 (3) :313-25.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Aurora A; PDGFRα; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Citation 01
Am J Pathol. 2019 Oct;189 (10) :2090-2101.|Int J Gynecol Cancer. 2017 Oct;27 (8) :1666-1674. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Am J Pathol. 2019 Oct;189 (10) :2090-2101.

Alternative Products